ImmuPharma Chairman explains why the Avion deal is so significant

ImmuPharma plc (LON: IMM) Non-Executive Chairman Tim McCarthy joins DirectorsTalk to discuss a licencing and development agreement with US speciality pharmaceutical company Avion. Tim talks us through the key highlights of the deal, provides background on Avion, the importance of this validation from an industry player, partners for other territories, the next key milestones, the Lanstead Agreement and why ImmuPharma is now a stock potential investors should be considering.

ImmuPharma is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Share this interview

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp
Immupharma plc
ImmuPharma Chairman explains why the Avion deal is so significant

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions